Filtered library · Archetype
Earnings inflection · 228 dossiers
Dossiers classified as Earnings inflection — 228 names, each with its thesis, invalidation trigger and catalyst calendar.
All 228 are dated research with a published kill line — the level named in advance that would prove the call wrong.
All dossiers IRDM Iridium Communications Inc fresh MEDIUM Iridium Communications’ merger-discount thesis now has completed financing behind it; acquisition completion before a weekly close below $43.50 settles the case. Rocket Lab’s 2026-09-15 funding announcement advances the transaction, while… OSCR Oscar Health, Inc. fresh MEDIUM Oscar Health's higher earnings outlook and quantified 2027 pricing support a post-Investor-Day rerating. A weekly close above $32.76 before a weekly close below $29.83 would complete the price-confirmation test; the September 18, 2026… CNC Centene Corporation fresh LOW Centene's margin-repair case requires sustained earnings guidance and a weekly close above $68.72 by its 2026-10-27 results. September's reaffirmation supports the earnings leg, but a weekly close below $65 or withdrawal or reduction of… APGE Apogee Therapeutics, Inc. fresh SUPREME Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst. ATAI AtaiBeckley Inc. fresh SUPREME AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14. DSGR Distribution Solutions Group, Inc. fresh SUPREME Distribution Solutions Group’s $35.00 cash acquisition remains a completion thesis, with the minority vote and closing settling the case. HSR clearance occurred on 2026-08-20; a daily close below $33.50 invalidates the price thesis. ATKR Atkore Inc. fresh HIGH Atkore's $95.00 cash-merger thesis now turns on the October 7 shareholder vote and remaining approvals after September 14 US antitrust clearance. Completion before a weekly close below $88 constitutes success; termination negates the case. BWMN Bowman Consulting Group Ltd. HIGH Bowman Consulting Group’s $43.00 cash acquisition makes merger completion the central thesis. The case resolves with payment of the announced consideration before a daily close below $40.50; the 2026-09-13 go-shop deadline narrows… CBZ CBIZ, Inc. fresh HIGH CBIZ’s signed $55.00 cash merger makes completion the central thesis; closing settles the case, while a daily close below $52 invalidates it. The expected 2026-09-10 antitrust milestone has elapsed, but its outcome and a shareholder-vote… HZO MarineMax, Inc. HIGH MarineMax’s $53.00-per-share cash merger prices completion of the Safe Harbor transaction on the announced end-2026 timetable. Closing would settle the case; a weekly close below $50, termination or failure to complete by 2026-12-31 would… ITGR Integer Holdings Corporation HIGH Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it. PSNL Personalis, Inc. fresh HIGH The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus… VREX Varex Imaging Corporation HIGH Varex Imaging Corporation’s $18.90 cash acquisition by Teledyne remains a completion thesis. The 2026-09-08 preliminary proxy advances the process; payment resolves the case, while a daily close below $17.50 invalidates it. ABCL AbCellera Biologics Inc. fresh MEDIUM AbCellera's monthly hot-flash antibody thesis requires the 2026-10-01 presentation to preserve the Phase 2 efficacy case and a subsequent weekly close above $12.73; a weekly close below $9.75 invalidates it. ABSI Absci Corporation fresh MEDIUM Absci Corporation’s valuation rests on ABS-201 delivering human hair-growth efficacy in the guided second half of 2026. Separation from placebo would validate the case; a weekly close below $7.50, absent efficacy or a missed readout window… ALVO Alvotech MEDIUM Alvotech's recovery prices in Q4 2026 FDA approvals after the Reykjavik inspection closure announced on 2026-07-29. AVT05 and AVT06 approvals within that window would confirm the regulatory-repair case; another manufacturing-related… AQST Aquestive Therapeutics, Inc. MEDIUM Aquestive Therapeutics' recovery thesis rests on an Anaphylm resubmission by 2026-09-30, following its August usability results. A filing announcement before a weekly close below $4.47 would satisfy the near-term case; missing the deadline… BBNX Beta Bionics, Inc. fresh MEDIUM Beta Bionics’ new case is Mint commercialization after the September revenue cut broke the iLet growth thesis. Full U.S. launch within management’s Q1 2027 window would confirm the case; a weekly close below $17.25 would invalidate it. CDNA CareDx, Inc. MEDIUM CareDx’s reimbursement repricing depends on its next quarterly report sustaining the $490–500 million revenue outlook issued on 2026-07-30. Canaccord’s 2026-09-02 initiation renewed attention, but a weekly close below $44 would invalidate… CMPS COMPASS Pathways Plc MEDIUM Compass Pathways’ September 9 COMP360 durability update renews the regulatory revaluation case ahead of its company-guided Q4 2026 submission. A weekly close above the September 11 series’ $15.17 52-week high would confirm the price… CRDL Cardiol Therapeutics Inc. Class A MEDIUM Cardiol Therapeutics’ enrollment-led re-rating requires MAVERIC completion by 2026-09-30 and a weekly close above $2.29 before a weekly close below $1.75. The 2026-09-10 preliminary shelf introduces financing capacity, but the announcement… FRNM Freenome, Inc. MEDIUM Freenome's approved blood-test story depends on Abbott launching SimpleScreen CRC and demonstrating reimbursed testing. Carelon's 2026-11-15 guideline strengthens the pathway; a weekly close below $14 or no US launch by 2026-12-31… GHRS GH Research PLC MEDIUM Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next… MANE Veradermics, Incorporated MEDIUM Veradermics’ oral minoxidil story depends on Study ‘304’ replicating the reported hair-growth benefit by year-end 2026. Failed replication, a weekly close below $85, or the reporting window expiring without results would invalidate the… MGTX MeiraGTx Holdings plc fresh MEDIUM The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 — a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but… NAVN Navan, Inc. fresh MEDIUM Q2 FY2027 prints 2026-09-09 with the first positive non-GAAP operating-income guide ($13.5–14.5M) on the line. Four target raises in 21 days — BofA $26→$34 on 09-02, Morgan Stanley $33 on 09-04 — landed while the shares fell from the… ORKA Oruka Therapeutics, Inc. MEDIUM Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B… PLSE Pulse Biosciences, Inc MEDIUM Pulse Biosciences’ faster trial-enrollment story depends on NANOPULSE-AF completion in early October. An announcement by 2026-10-31 before a weekly close below $44 would validate the schedule thesis; the 2026-09-09 analyst initiation adds… SMMT Summit Therapeutics Inc. fresh MEDIUM Summit Therapeutics’ ivonescimab thesis is that quantified survival evidence converts into US approval by 2026-11-14 before a weekly close below $15.00. September’s disclosures strengthen the clinical case, but the global trial’s primary… TVTX Travere Therapeutics, Inc. fresh MEDIUM Travere Therapeutics’ FILSPARI expansion needs another quarter of sales and patient-start growth to confirm its commercial narrative. A weekly close above $67.52 completes the price case; a weekly close below $58 invalidates it. VSTM Verastem, Inc. MEDIUM Verastem’s commercial launch supports a VS-7375 clinical revaluation thesis, tested by the newly scheduled 2026-10-14 efficacy update. The case requires reported tumor responses and a daily close above the 2026-09-02 reference close of… ZLAB Zai Lab Limited MEDIUM Zai Lab's global drug-development re-rating depends on October's zoci data leading to first-line lung-cancer Phase 3 initiation by 2026-12-31. The case requires those milestones before a weekly close below $22; the partnered ALKIVIA… AMLX Amylyx Pharmaceuticals, Inc. fresh LOW Amylyx Pharmaceuticals’ avexitide story now depends on a year-end 2026 NDA submission and recovery above the $35.50 offering price. An announced submission and a weekly close above that level complete the case; a weekly close below $30… ASMB Assembly Biosciences, Inc. LOW Assembly Biosciences confirmed its Gilead profit-share option on 2026-09-08, but its momentum thesis failed at the September 11 close below $30. The remaining development case requires GS-1179 to enter Phase 2 by year-end 2026; a disclosed… BLSH Bullish LOW Bullish's regulatory repricing thesis requires successful CLARITY Act cloture followed by a weekly close above $37.10 before a weekly close below $31. The September 15, 2026 milestone is motion ripening, while the September 9 close of… BMEA Biomea Fusion, Inc. fresh LOW Biomea Fusion’s icovamenib thesis depends on lasting glucose control after limited treatment. COVALENT-211 must meet its placebo-controlled primary endpoint in the company-guided Q1 2027 window before a weekly close below $1.60 invalidates… CLYM Climb Bio, Inc. fresh LOW Climb Bio's re-rating depends on Q4 2026 budoprutug patient data establishing clinical benefit. Recovery of the $17.84 adjusted annual high would confirm the price leg; a weekly close below $13.30 or a delay beyond the guided clinical… CRCL Circle Internet Group, Inc. LOW Circle Internet Group's Arc-led infrastructure breakout failed when its 2026-09-09 close of $92.99 breached the published $95 boundary. The scheduled 2026-09-16 public launch still tests delivery, while any recovery case requires renewed… FDMT 4D Molecular Therapeutics, Inc. LOW 4D Molecular Therapeutics’ durability thesis needs timely Q3 clinical execution to restore the advance; a weekly close above the August 21 reference of $15.83 would complete the recovery case before a weekly close below $12.50 invalidates… GPRK Geopark Limited LOW GeoPark's Venezuela redevelopment deal creates a revaluation case. A weekly close above the $11.97 reference high would confirm the price thesis before a weekly close below the September 11 reference close of $11.48 invalidates it. IMMX Immix Biopharma, Inc. LOW Immix Biopharma’s NXC-201 story hinges on late-September data extending the reported 95% response rate across more patients. Confirmation requires that update by 2026-09-30 before a weekly close below $11.00; company language does not… INBX Inhibrx Biosciences, Inc. LOW Inhibrx Biosciences’ advance prices HexAgon clinical success and a Phase 3 start within the guided quarter. The 2026-09-08 results and September start confirmation test that case; a weekly close below $104 or reported primary-endpoint… INSP Inspire Medical Systems, Inc. LOW Inspire Medical Systems' rally prices a recovery from reimbursement disruption. A weekly close at or above Stifel's September 11, 2026 target of $80 would confirm the price case, while a weekly close below the September 11 reference close… KURA Kura Oncology, Inc. LOW The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A… NVAX Novavax, Inc. LOW Novavax's Matrix-M royalty re-rating needs company-confirmed Sanofi trial timing at the 2026-09-09–2026-09-10 conferences. The near-term case fails if both pass without that timing or a weekly close falls below $9.00. ODD ODDITY Tech Ltd. fresh LOW Broken compounder with exactly one dated event: the 2026-09-09 pre-market Q2 print. Price ran $13.22 (2026-08-21) to $14.35 (2026-08-28) on no company disclosure since 2026-07-22, leaving it ~30% above the $11.07 consensus target of 10… PANL Pangaea Logistics Solutions Ltd. LOW Dry-bulk recovery is in the P&L but not the tape: Q1 2026 (2026-05-11) adjusted EBITDA +70% YoY to $25.2M on $15,252/day TCE, yet the stock closed $7.42 on 2026-08-07, 20.1% under the $9.29 52-week high. The 2026-08-10 Q2 print is the… QRVO Qorvo, Inc. fresh LOW Qorvo trades as a fixed-ratio merger spread: 0.960 SWKS plus $32.50 cash. Skyworks' $74.02 close on 2026-09-04 implies $103.56 against Qorvo's $102.84 — about 0.70% gross, the thinnest of this coverage, after the acquirer rallied 12.5% in… RPD Rapid7, Inc. fresh LOW Rapid7's cost-cutting recovery needs Q3 2026 results to meet revenue and recurring-revenue guidance while preserving the 20% Q4 adjusted operating-margin goal. A weekly close below $10.60 or withdrawal of that goal invalidates the case. TNET Trinet Group, Inc. fresh LOW TriNet Group’s margin recovery depends on Q3 insurance costs holding below 89.5% without July’s nonrecurring benefit. The case resolves positively if FY2026 earnings and revenue guidance also hold before a weekly close below $65… UPXI Upexi, Inc. LOW Upexi’s Solana-discount recovery requires positive audited net assets and a Nasdaq bid-price cure. The September 28 annual-report checkpoint is provisional, while a weekly close below $1.00 invalidates the recovery structure. WGS GeneDx Holdings Corp. fresh LOW Busted-growth genomics name; the recovery off the −49% May guide-cut crash has stalled in the low-$60s, below the $74.83 200-day. The confirmed Aug 3 Q2 print (blended ARR vs the ~$3,300 baseline) is the binary — the same day as the… XNCR Xencor, Inc. LOW Xencor’s post-settlement re-rating depends on October XmAb819 data supporting a pivotal-dose choice and the planned 2027 study. A weekly close below $23.34 or withdrawal of that timetable invalidates the continuation case. ALOT AstroNova, Inc. fresh SUPREME AstroNova’s $29.00 cash-merger thesis played out on 2026-08-26; its 2026-09-08 Form 15 resolves the remaining filing uncertainty. Only restoration of the former public equity would reopen the closed situation. AVNS Avanos Medical, Inc. fresh SUPREME Avanos Medical’s $25.00-per-share cash-acquisition thesis was settled by completion on 2026-07-27. The company’s shareholder notice confirms that exchange trading has ended, leaving a completed transaction rather than an unresolved… CCRN Cross Country Healthcare, Inc. fresh SUPREME Cross Country Healthcare’s $13.25 cash-merger thesis resolved when Knox Lane completed the acquisition on 2026-07-21. Exchange-confirmed trading in the original common stock would contradict the completed-outcome assessment; the July 20… CNTA Centessa Pharmaceuticals plc fresh SUPREME Centessa Pharmaceuticals’ acquisition closed on 2026-06-24; the remaining story is approval-linked contingent value. Qualifying regulatory approvals settle that question, while the final CNTA close on 2026-06-23 supplies no live price test. CRNX Crinetics Pharmaceuticals, Inc. fresh SUPREME Crinetics Pharmaceuticals’ cash-merger thesis was resolved by Vertex’s 2026-09-01 acquisition at $85.00 per eligible share. Deregistration dates remain unverified; reinstated common-stock trading would overturn the terminal-equity… FBRX Forte Biosciences, Inc. fresh SUPREME Forte Biosciences’ $77-per-share cash-acquisition thesis was resolved by the 2026-08-27 merger completion. Official restoration of the former common equity would reopen the case; Nasdaq records 2026-08-26 as its last trading date. KALV KalVista Pharmaceuticals, Inc. fresh SUPREME KalVista Pharmaceuticals’ $27.00 cash-acquisition thesis was settled by Chiesi’s 2026-06-11 completion announcement. A renewed equity thesis would require documented restoration of the original common stock; the provisional September… LPRO Open Lending Corporation fresh SUPREME Open Lending Corporation’s $3.15 cash-acquisition story concluded with ANV’s confirmed completion on 2026-07-30. The public-equity narrative remains closed unless an official reversal or documented restoration of trading reopens it. NUVL Nuvalent, Inc. fresh SUPREME Nuvalent’s independent equity story ended with GSK’s $124-per-share acquisition on 2026-07-15. The 2026-09-14 zidesamtinib update advances GSK’s clinical portfolio; only an official restoration of the former listed equity would reopen the… OLPX Olaplex Holdings, Inc. fresh SUPREME Olaplex Holdings’ cash-acquisition thesis was resolved by Henkel’s 2026-07-07 completion and the end of Nasdaq trading. A newly listed standalone security would reopen equity analysis; Henkel’s 2026-11-10 release addresses only the… TBRG TruBridge, Inc. fresh SUPREME TruBridge’s $26.25-per-share cash acquisition completed on 2026-07-09, ending its standalone equity catalyst. September leadership integration concerns the acquirer; only an official restoration of the original listed equity would reopen… ARX Accelerant Holdings HIGH Accelerant Holdings’ $20.25 cash acquisition by Thoma Bravo remains a completion thesis, with closing guided to the first half of 2027. Completion settles the case; a daily close below $18.25 or deal termination invalidates it. ESPR Esperion Therapeutics, Inc. HIGH Esperion Therapeutics’ cash-merger thesis was settled by the 2026-07-13 acquisition; only conditional commercial milestones remain. The common stock ceased trading, so the historical price invalidation no longer provides a prospective test. GBTG Global Business Travel Group, Inc. fresh HIGH Global Business Travel Group’s $9.50-per-share Long Lake cash acquisition remains the thesis: completion settles the case, while a daily close below $9.00 invalidates it. Shareholders approved the merger on 2026-08-03, but the verified… MKTX MarketAxess Holdings, Inc. HIGH MarketAxess’s $167-per-share cash acquisition by Intercontinental Exchange remains a completion story. Completion before a daily close below $155 would validate the case; the September 25, 2026 antitrust milestone is the next dated test. OGN Organon & Co. fresh HIGH Organon & Co.’s $14.00-per-share cash acquisition by Sun Pharma remains a completion thesis. Payment of the agreed consideration before a daily close below $13.00 would settle the case; the 2026-07-23 shareholder approval leaves regulatory… PAYO Payoneer Global Inc. fresh HIGH Payoneer Global's $7.40-per-share cash acquisition now hinges on regulatory clearance and completion after September 14 shareholder approval. Payment before a daily close below $6.75 would resolve the thesis favorably; the vote alone does… RAMP LiveRamp Holdings, Inc. fresh HIGH LiveRamp’s $38.50-per-share cash acquisition by Publicis remains a regulatory-completion thesis. Publicis reaffirmed year-end completion on 2026-09-16; closing by 2026-12-31 confirms the case, while a daily close below $35, termination or… SAFT Safety Insurance Group, Inc. fresh HIGH Safety Insurance Group’s $105.00 cash-merger completion case now has HSR clearance and a 2026-11-03 shareholder vote. Completion requires the remaining approvals, while a daily close below $99 invalidates the price-convergence thesis. SMTI Sanara MedTech Inc. HIGH Sanara MedTech's cash-and-stock acquisition by MIMEDX now has a 2026-09-30 shareholder vote; completion by year-end would settle the merger thesis. A daily close below $32.50 or failure to complete by 2026-12-31 invalidates that case. TECH Bio-Techne Corp fresh HIGH Bio-Techne’s $73.00 cash acquisition by Merck KGaA remains a completion thesis, with the shareholder vote scheduled for 2026-09-23. The case resolves through payment after required approvals and is invalidated by a daily close below $70;… UTZ Utz Brands, Inc. HIGH Utz Brands’ $14.25 cash-acquisition story turns on completion in the company-guided fourth quarter of 2026. Closing fulfills the case; a daily close below $13.50 or failure to complete by 2026-12-31 invalidates it, while the September 11… ABVX Abivax SA fresh MEDIUM Abivax's recovery case requires a late-2026 obefazimod US filing and a weekly close above the July offering price of $125 by 2026-12-31, before a weekly close below $96 invalidates it. The 2026-09-21 results provide the next scheduled test… AGIO Agios Pharmaceuticals, Inc. fresh MEDIUM Agios Pharmaceuticals' mitapivat label-expansion thesis turns on FDA approval for sickle cell disease by 2026-11-01. Approval would validate the regulatory case; a weekly close below $29 would invalidate the price structure first. BOLD Boundless Bio, Inc. fresh MEDIUM Boundless Bio’s merger thesis pairs a planned $44–48 million cash distribution with a minority Serapha interest. Completion by 2026-12-31 with that distribution intact would confirm the case; a weekly close below $2.40 would invalidate its… CCC CCC Intelligent Solutions Holdings Inc. MEDIUM Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is… CGEM Cullinan Therapeutics, Inc. fresh MEDIUM CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout… CLOV Clover Health Investments, Corp. fresh MEDIUM Clover Health's rating-led profitability thesis has fresh analyst coverage but still depends on the court-supported reimbursement remedy. A weekly close above the $5.41 reference high with its raised FY2026 outlook intact would confirm… DRTS Alpha Tau Medical Ltd. MEDIUM Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +… DYN Dyne Therapeutics, Inc. MEDIUM Nothing company-dated until the ~late-October Q3 print, leaving a maturing narrative to trade on small-cap biotech flow ahead of the 2027-01-21 PDUFA. ELF e.l.f. Beauty, Inc. fresh MEDIUM Sell-side flipped from cutting to marking up in ten days — five PT raises 2026-07-10→07-17 (JPM $94, Canaccord $97, Citi $92, RJ $87, UBS $80) on the e.l.f. Hair launch and Rhode scaling, while the stock slipped to $72.25. Narrative… GERN Geron Corporation fresh MEDIUM The leg is a self-funding commercial ramp, not the myelofibrosis binary: Q2 RYTELO revenue $57.5M (+11% QoQ), quarterly cash draw down to ~$14M on $326.9M, FY guide $220–240M reiterated at the mid-to-high end. The 2026-09-02 release added… IDYA IDEAYA Biosciences, Inc. fresh MEDIUM IDEAYA Biosciences' darovasertib filing and expansion trials underpin a recovery thesis. Confirmation requires a weekly close above the $42.48 reference high and NDA completion by 2026-12-31 before a weekly close below $34; the October… IRWD Ironwood Pharmaceuticals, Inc. fresh MEDIUM Ironwood Pharmaceuticals’ LINZESS cash generation supports a recovery toward the market’s $5.39 high, tested by annual guidance and year-end debt reduction. A weekly close above $5.39 completes the price case; a weekly close below $3.80… IVA Inventiva S.A. fresh MEDIUM The 30-day news blackout broke: the 2026-09-02 last-patient-last-visit release in NATiV3 (1,419 patients) reaffirmed Q4 2026 topline and closed the trial-conduct timing gate, leaving database lock and unblinding as the only steps before… MBX MBX Biosciences, Inc. fresh MEDIUM MBX Biosciences' funded once-weekly hormone-replacement program anchors the valuation story, with Q4 2026 obesity data the next clinical test. The price case requires a weekly close above the $70.70 reference high before a weekly close… MIRM Mirum Pharmaceuticals, Inc. fresh MEDIUM Rare-disease franchise ran to a $125 ATH on FOP data, then cooled ~9% into a confirmed 2026-07-30 Q2 print. Base compounds (Q1 sales +43% YoY, FY guide $660–680M) with FOP PDUFA 2026-09-26 and HDV Phase 3 topline 2H26 stacked ahead — but… MNPR Monopar Therapeutics Inc. fresh MEDIUM The rolling-NDA leg rebuilt without news: $107.72 on 2026-08-21 to $117.56 on 2026-09-04, back within 5.1% of the $123.84 high, on no company release since 2026-08-19 and with two directors selling into $109–$113 on 2026-08-25 and… NKTR Nektar Therapeutics fresh MEDIUM M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh… PEB Pebblebrook Hotel Trust fresh MEDIUM Pebblebrook Hotel Trust’s lodging recovery requires October 29 results to sustain its raised earnings outlook before the $16 breakout shelf fails. The case resolves positively if third-quarter RevPAR growth exceeds +1% and annual guidance… PGEN Precigen, Inc. fresh MEDIUM PAPZIMEOS launch-ramp durability is the binary — the first FDA-approved RRP therapy printed $21.6M net product revenue in Q1 2026, and the now-confirmed Aug 4 Q2 print (announced Jul 21) grades whether the ramp compounds sequentially or… PTGX Protagonist Therapeutics, Inc. fresh MEDIUM De-risked dual-royalty story accelerating into a binary: icotrokinra (oral IL-23, J&J) already approved and paying 6–10% royalties; rusfertide (PV, Takeda) into a Q3 2026 PDUFA. Stock at a fresh ATH ($143.29, Jul 20) as the PV theme runs —… PVLA Palvella Therapeutics, Inc. fresh MEDIUM Palvella Therapeutics’ QTORIN filing puts an accelerated FDA review in focus. Acceptance with Priority Review and a weekly close above $157.77 would complete the case before a weekly close below $137 invalidates it; the filing… RAPP Rapport Therapeutics, Inc. fresh MEDIUM RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news — the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.… RLYB Rallybio Corporation fresh MEDIUM Rallybio’s Avenzo merger thesis combines a cash distribution with residual oncology exposure; completion and a declared distribution would establish the outcome. A weekly close below $14 invalidates the price case, while failure to close… RMAX Re/Max Holdings, Inc. fresh MEDIUM Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80… SNDX Syndax Pharmaceuticals, Inc. MEDIUM Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance… SWKS Skyworks Solutions, Inc. fresh MEDIUM Skyworks Solutions' Qorvo merger story supports further repricing, with a weekly close above the September 18 high of $91.32 defining success. A weekly close below $84.40 invalidates the price thesis; completion beyond calendar 2026 would… TRVI Trevi Therapeutics, Inc. fresh MEDIUM Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional… ULCC Frontier Group Holdings, Inc. fresh MEDIUM Fuel-relief leg replaced by an earnings-delivery leg: the 2026-07-29 Q2 print put adjusted EPS at $(0.10) against a $(0.60)–$(0.45) May guide on record $1,279M revenue, and guided 2H to breakeven-or-better. The catch is that guide assumes… USO United States Oil Fund, LP MEDIUM The driver rotated: Rubio's 2026-08-25 shift from strikes to sanctions drained the escalation bid, but EIA's 0.095M bbl crude build vs 1.600M expected (08-26) and oil rigs -5 to 447 vs 454 est (08-28) carried USO to $129.70. The narrative… VRNS Varonis Systems, Inc. fresh MEDIUM Varonis Systems' takeover story depends on reported Proofpoint talks producing a signed offer above the September 18 close of $47.56. A weekly close below $41 or confirmed termination of the talks invalidates the thesis. WDAY Workday, Inc. fresh MEDIUM The 2026-08-27 print removed the fundamental leg of the bear case — cRPO +14.2% inside the guided 13.5–14.5% band, FY27 margin guide lifted to 31.0%, a new $4.0B buyback — while the Q3 cRPO guide of 11–12% sits under the ~13.3% consensus.… ZBIO Zenas BioPharma, Inc. MEDIUM First-in-disease B-cell modulator: obexelimab BLA (IgG4-RD, 56% flare cut, HR 0.44) hit the FDA 2026-05-28, and the ~60-day filing determination — acceptance plus a possible Priority Review grant — is due within days, a fresh near-term… ZYME Zymeworks Inc. fresh MEDIUM Zymeworks’ Ziihera approval supports royalty growth; Q3 2026 royalties must exceed Q2’s $1.8 million to confirm the next commercial step. A weekly close below $25 invalidates the market case before that confirmation. AAPL Apple Inc. LOW July's rotation-crown has slipped — Polymarket now gives Apple 20% odds of ending 2026 as the largest company (7/24) and semis are breaking out again (NVDA 7/23). The live narrative is the 'anti-CapEx AI trade' as Alphabet turns… ABEO Abeona Therapeutics Inc. LOW The post-print drift has continued without repair: the 2026-08-28 close of $5.92 sits two cents above the $5.90 shelf the prior note named as the break, with RSI(14) at 21.8 and no Abeona press release at all between 2026-08-13 and… ACB Aurora Cannabis Inc. fresh LOW Aurora Cannabis's takeover thesis requires improved Curaleaf terms or a competing definitive offer before a weekly close below $3.40. Curaleaf's 2026-09-14 regulatory application advances the dispute, but its 2026-09-15 letter retained… ACDC ProFrac Holding Corp. fresh LOW ProFrac's frac-pricing recovery has September financing relief, but operating confirmation is missing. The case requires Q3 stimulation margin above the 9% reported on 2026-08-06 and a weekly close above the August reference of $5.37… ACLS Axcelis Technologies, Inc. fresh LOW Axcelis has stopped falling without being re-bid: $115.57 on 2026-08-28 to $115.08 on 2026-09-04, RSI(14) down to 22.0, 39.9% under the $191.6 high. What is left is a de-rated implant franchise plus an undated China SAMR ruling into the… AIRO AIRO Group Holdings, Inc. LOW AIRO Group Holdings’ recovery case rests on drone backlog conversion after the September tariff narrative failed. A Nord Drone closing by 2026-09-30 and a weekly close above the broken $8.00 level would establish the near-term case; a… AKBA Akebia Therapeutics, Inc. fresh LOW VOICE outcomes win (USRC trial stopped early, June 2026) de-risked Vafseo's dialysis-anemia case, but the tape bled to ~$1.22, only ~48% above the $0.82 low and still fading; the late-July/early-August Q2 print is the binary —… ALHC Alignment Healthcare, Inc. fresh LOW Profitable-MA-disruptor narrative broke on 2026-07-08: a whistleblower suit from a former Chief Transformation Officer alleges the +88% adjusted-EBITDA inflection was manufactured by reclassifying opex as capex across FY2024-25. Shares… ALMS Alumis Inc. fresh LOW The lupus leg is gone: LUMUS missed BICLA at Week 48 and every secondary in the overall 408-patient population on 2026-09-01, and the stock closed 2026-09-04 at $11.10 with RSI(14) at 18.2, 63.4% below the $30.30 high. What is left is a… ANAB AnaptysBio, Inc. fresh LOW AnaptysBio’s Jemperli rights-reversion thesis turns on a written Chancery judgment; the September 25 brief advances the case without settling it. A judgment granting reversion before a weekly close below $52 would establish the thesis… ANRO Alto Neuroscience Inc. fresh LOW Alto Neuroscience’s funded depression-trial program supports a recovery case, but September price weakness lowers conviction. A weekly close above $36.64 would establish recovery before a weekly close below $28 invalidates it; PACE-2 must… ARCT Arcturus Therapeutics Holdings Inc. LOW Arcturus Therapeutics’ regained vaccine rights underpin a revaluation thesis that requires ARCT-810 data and a stated regulatory development path by 2026-09-30. Missing that disclosure boundary or a weekly close below $12 invalidates the… ARTV Artiva Biotherapeutics, Inc. fresh LOW Artiva Biotherapeutics’ AlloNK thesis hinges on expanded rheumatoid arthritis data and pivotal-trial initiation by year-end 2026. Those milestones must arrive before a weekly close below $8.61 invalidates the market case. ASTS AST SpaceMobile, Inc. LOW AST SpaceMobile’s spectrum-access recovery requires a disclosed Grain agreement and a weekly close above $62.40 by 2026-11-05. A weekly close below $55.74 would invalidate the case first. AVLN Avalyn Pharma Inc. fresh LOW Avalyn Pharma’s inhaled-antifibrotic re-rating depends on recovering the September 4 market close of $37.39 before a weekly close below $30. The September 8 modeling release left clinical efficacy unresolved ahead of MIST results guided to… AVTX Avalo Therapeutics, Inc. fresh LOW Avalo Therapeutics' abdakibart recovery case rests on funded Phase 3 development; fuller LOTUS data and a weekly close above the September 4 reference of $19.23 would confirm it. A weekly close below $16 invalidates the case. AVXL Anavex Life Sciences Corp. LOW Anavex Life Sciences’ governance rerating thesis failed its price test: the 2026-09-11 close of $2.62 breached the published $2.75 weekly threshold. The 2026-09-24 board vote still settles control, but it cannot reverse that recorded… BAK Braskem S.A. fresh LOW Braskem's restructuring recovery depends on a binding parent plan that preserves listed equity without creditor-driven dilution. The 2026-09-24 subsidiary hearing tests the first agreement; the estimated 2026-11-22 parent creditor-support… BCAX Bicara Therapeutics Inc. LOW Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,… BHVN Biohaven Ltd. LOW Biohaven's recovery case rests on SK licence funding and removal of the opakalim enrollment hold. Completion of both and a weekly close above $14 would establish recovery; a daily close below $12.71 invalidates it, while the earlier… BIOA BioAge Labs, Inc. LOW BioAge Labs' recovery hypothesis links September 8 clinical progress to a weekly reclaim of $9.00 before a weekly close below $8.49. The prior shelf thesis failed on September 11; QUELL-CV results remain the next test of biomarker efficacy. BTGO BitGo Holdings, Inc. LOW Broken IPO that cleared its 2026-07-21 lockup without a supply flood but is grinding on the $4.665 all-time low with no bounce; Goldman cut its target to $7.75, and the undated $100M Galaxy verdict plus the ~2026-08-26 Q2 print are the… BVS Bioventus Inc. LOW Bioventus's acquisition-review thesis requires a definitive acquisition agreement above the 2026-09-11 close of $12.98 before a weekly close below $12.50. The August 5 proposal disclosure supports the case, but the review has no deadline… BWIN The Baldwin Insurance Group, Inc. LOW Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M,… CABA Cabaletta Bio, Inc. fresh LOW Autoimmune CD19 CAR-T reset story, now funded — $225.1M cash at 2026-06-30, runway into mid-2027 — but registrational RESET-Myositis data are guided to mid-2027 and the BLA to 2H27, so no clinical datapoint resolves inside 30 days.… CADL Candel Therapeutics, Inc. fresh LOW Candel Therapeutics’ recovery case requires a weekly reclaim of $11.80 and its planned Q4 2026 prostate-cancer filing before a daily close below $10.85. The September 18 close already invalidated the previous momentum thesis. CAL Caleres Inc fresh LOW Q2 was pulled forward one day to 2026-09-09 (announced 2026-09-01), compressing the read into a single session: FY2026 consensus of $1.62 adjusted EPS sits at the top of the company's own $1.40–$1.65 guide, Famous Footwear is guided down… CCXI Churchill Capital Corp XI fresh LOW De-SPAC humanoid pure-play still bleeding premium: $17.07 (2026-08-14) → $14.57 (2026-08-21) → $13.40 (2026-09-04), RSI(14) down to 25.9. The only company-dated item since the 2026-07-14 confidential S-4 is an 2026-08-27… CGC Canopy Growth Corporation fresh LOW The rescheduling binary CGC trades on came and went: the DEA hearing closed 2026-07-15 with no verdict, briefs due 2026-08-17 and the ALJ recommendation undated into H2 2026, likely litigated into 2027. Shares closed $0.89 on 2026-07-24,… CHYM Chime Financial, Inc. fresh LOW Busted-IPO fintech: operations accelerating (Q1 rev +25% to $647M, first GAAP profit, FY guide raised to $2.66–2.69B) but the stock trades ~19% below its $27 IPO and bases near post-IPO lows — a compressed multiple, not an accelerating… CLDX Celldex Therapeutics, Inc. LOW Celldex Therapeutics’ barzolvolimab case requires both Phase 3 CSU trials to meet their primary efficacy endpoints by 2026-10-31 before a weekly close below $35. The 2026-09-11 close of $36.90 leaves the structural case unresolved ahead of… CNMD CONMED Corporation fresh LOW CONMED Corporation's sale-premium thesis failed its published $46 weekly-close test on 2026-09-18. A disclosed transaction would establish a new deal case; September operating commentary has not resolved the July sale report. CORT Corcept Therapeutics Incorporated LOW Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry… CRTO Criteo S.A. LOW Criteo's recovery case rests on ChatGPT advertising translating into financial stabilization. Q3 contribution excluding traffic acquisition costs reaching $241 million without another annual outlook cut would validate it; a daily close… CRVS Corvus Pharmaceuticals, Inc. LOW Corvus Pharmaceuticals’ soquelitinib recovery case requires a weekly close above the August 28 close of $14.16 before a weekly close below $12.50. Angel’s eczema results, guided on August 6 to late 2026, remain the next clinical test;… DFTX Definium Therapeutics, Inc. LOW Definium Therapeutics’ recovery thesis turns on September’s Panorama anxiety trial confirming DT120 efficacy and restoring the pre-readout price structure. Success requires a positive primary endpoint and a weekly close above $46.14 before… DNTH Dianthus Therapeutics, Inc. LOW Dianthus Therapeutics’ claseprubart re-rating depends on supportive December clinical evidence and a dated pivotal readout. The price case requires a weekly close above $115.96 by 2026-12-31 before a weekly close below $100 invalidates it. DSGN Design Therapeutics, Inc. fresh LOW Design Therapeutics’ frataxin-biomarker thesis depends on its Q4 2026 update establishing a regulatory path for DT-216P2. Supportive FDA feedback and a defined registrational design would substantiate the case; a weekly close below $13.50… DTIL Precision BioSciences, Inc. LOW Precision BioSciences’ hepatitis B gene-editing thesis needs replicated liver-biopsy results by year-end 2026. The case succeeds if additional patients show cccDNA reduction without treatment-limiting safety findings before a weekly close… ELVN Enliven Therapeutics, Inc. LOW Enliven Therapeutics’ re-rating case depends on starting the pivotal ELVN-001 trial within its guided second half of 2026. Disclosed initiation and a weekly close above the $61.15 high recorded on 2026-09-11 would confirm the case before a… EPC Edgewell Personal Care Company fresh LOW Edgewell Personal Care's takeover-and-recovery thesis needs renewed deal evidence or confirmed growth to restore the market's $29.50 high. A weekly close above $29.50 would complete the price case; a weekly close below $25 would invalidate… ERAS Erasca, Inc. LOW FDA Fast Track for ERAS-0015 in metastatic pancreatic (2026-08-24) landed on 16.4x average volume for a -0.17% close; J.P. Morgan then marked to a street-high $33 on 2026-08-27 while the 2026-08-28 close was $18.03 against a $23.5… EVH Evolent Health, Inc fresh LOW The late-June retail bounce has fully unwound — EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which… FIG Figma, Inc. fresh LOW Design incumbent re-rated as an AI winner (BofA Buy, $30 PT, 7/7) rather than an AI casualty, yet the stock churns below its 100/200-day moving averages with heavy short interest into its first public earnings print on 8/5 — that print,… FOUR Shift4 Payments, Inc. LOW Payments roll-up at ~$50, a hair above its $46.26 52-week low set on a 2026 guide-down. The Global Blue tax-free-shopping integration ("Shift4 One," launched 2026-07-14) is the transformation leg, but the 2026-07-30 Q2 print is the binary… FWRD Forward Air Corporation LOW Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited… GCO Genesco Inc. fresh LOW The operating turnaround is real but priced, and its one asymmetric leg — the activist proxy fight — lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the… GLUE Monte Rosa Therapeutics, Inc. fresh LOW ZEUS (ziltivekimab, MACE HR 0.99) failed on 2026-07-31 and took GLUE −27.16% to $16.52, its worst session on record, because the hsCRP-to-outcomes link under MRT-8102's ASCVD story is exactly what ZEUS could not demonstrate. Platform,… GSHD Goosehead Insurance, Inc. fresh LOW Goosehead Insurance’s recovery case requires renewed core-revenue growth and a weekly reclaim of $64 after the September 18 structural failure. Q3 core growth above 10% would confirm the operating leg; a weekly close below $54.28 would… HOV Hovnanian Enterprises, Inc. Class A LOW The housing-bill leg is spent — the Act auto-enacted 2026-07-11 and nothing dated has replaced it — yet HOV has re-rated to $137.78 (2026-08-07), 11.8% off the $156.16 high, on no company news. The confirmed 2026-08-20 Q3 print (quarter… HPP Hudson Pacific Properties, Inc. LOW Hudson Pacific Properties’ recovery case rests on leasing gains overcoming the cash restrictions disclosed on 2026-09-11. A weekly close above the August reference level of $14.50 would confirm the price recovery; a weekly close below $12… HROW Harrow, Inc. fresh LOW Show-me on an H2 ramp with nothing company-dated to resolve it before the ~November Q3 print: the reaffirmed $350–365M FY2026 guide needs the back half to roughly double H1's $114.9M against $292.4M loans payable net, and sell-side FY… IHRT iHeartMedia, Inc. LOW M&A leg is dead — no SiriusXM headline since the 2026-05-29 NYT "stalled" report and the April spike fully round-tripped ($6.33 high → $3.86 on 2026-08-07, -39%). What is left is a binary: Q2 print 2026-08-10 after the close is the first… IKT Inhibikase Therapeutics, Inc. fresh LOW Inhibikase Therapeutics’ Phase 3 execution could restore its pulmonary arterial hypertension re-rating. A weekly close above the September 18, 2026 reference high of $2.52 would establish the price case; a weekly close below the July… IMRX Immuneering Corporation fresh LOW Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap… IMVT Immunovant, Inc. fresh LOW Immunovant’s recovery case depends on IMVT-1402 clinical progress restoring the market’s $44.96 reference high by December 31, 2026. A weekly close below $35 invalidates the case; the September 18 three-month decline and undated clinical… IONQ IonQ, Inc. LOW IonQ's combined-company guidance restores a measurable revenue story; a weekly close above $44 would establish price repair. A weekly close below $36 first would invalidate that recovery case. JBIO Jade Biosciences, Inc. fresh LOW Jade Biosciences' JADE101 dosing story supports a conditional recovery case, but patient efficacy remains unresolved. A weekly close above the lost July $21 shelf would establish price repair; a weekly close below the June offering… JBLU JetBlue Airways Corporation fresh LOW Fuel-reversion bull leg broke: Brent re-spiked to ~$86 (Jul 17) on renewed Mideast conflict, reversing the sub-$73 tailwind the whole trade needed. Raymond James (Jul 6) cut to Underperform flagging a Chapter 11 that wipes equity; $9.3B… JELD JELD-WEN Holding, Inc. fresh LOW JELD-WEN's post-2026-08-03 re-rating has stalled: the 2026-09-04 close of $2.30 is back below the 2026-08-28 close of $2.53, RSI(14) has cooled from 71.2 to 61.0, and no company disclosure has landed since the 2026-08-05 analyst updates.… JOBY Joby Aviation, Inc. fresh LOW eVTOL cert story still advancing (FAA TIA testing, 2026 Dubai target) but the trade rolled over: ~$8 testing support, down ~33% since June 1, recovery base gone, CFO sold ~half his stake June 8, consolidation coverage marks sentiment… KOD Kodiak Sciences Inc fresh LOW Kodiak Sciences' repricing case rests on September DAYBREAK success and a weekly recovery above the former $36 shelf. Both investigational arms must meet their primary endpoints, while a weekly close below $32 invalidates the setup. LBRX LB Pharmaceuticals Inc LOW LB Pharmaceuticals’ funded schizophrenia trial supports a recovery thesis, tested by a weekly close above $49.48 before a weekly close below $42.80. NOVA-2 results guided for the first half of 2027 settle the separate clinical question. LOVE The Lovesac Company fresh LOW The 2026-08-27 notice made the binary real: Q2 FY27 lands before the open on 2026-09-10 against a company bar of $157–166M net sales and −$4M to +$2M adjusted EBITDA. Price closed $16.69 on 2026-09-04, under the 50-day at $16.95 and above… LQDA Liquidia Corporation fresh LOW Liquidia Corporation’s recovery case rests on YUTREPIA sales growth and a reclaim of the published $70 shelf. A weekly close above $70 plus next-quarter product sales above Q2 2026’s $170.4 million would confirm the case; a weekly close… LRMR Larimar Therapeutics, Inc. fresh LOW Single-asset FA regulatory binary sitting on the line that defines it: the week ending 2026-09-04 closed $3.83, 0.8% above the twice-tested $3.80 shelf, after five weeks with no company press release since the 2026-08-04 Q2 update. The… MAZE Maze Therapeutics, Inc. fresh LOW APOL1 kidney proof-of-concept intact and funded into 2029, but the only news since the last note was a conference calendar: the 2026-09-02 release scheduled fireside chats on Sept 9, 10 and 15 and repeated the late-2026/early-2027 HORIZON… MESO Mesoblast Limited fresh LOW Mesoblast’s Ryoncil-funded pipeline thesis faces a sales-growth test at the next quarterly report and weakening price support. A weekly close above the 2026-07-15 high of $18.07 would complete the recovery case; a weekly close below $15… MGM MGM RESORTS INTERNATIONAL fresh LOW Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low — so the trade is now a bump handicap, not a growth story. At… MGNX MacroGenics, Inc. fresh LOW MacroGenics' MGC026 revaluation thesis turns on the 2026-10-23 cancer-data presentation. Cohort-level response and durability evidence followed by a weekly close above $4.86 would confirm the case; a weekly close below $3.90 invalidates it. MMYT MakeMyTrip Limited fresh LOW MakeMyTrip's mid-year recovery bounce has stalled: after reclaiming the 200-day near $55, MMYT rolled back to ~$49, below both the 50- and 200-day, straight into an August 3 Q1 FY2027 print where consensus models EPS down ~76% YoY on ~137x… NGNE Neurogene Inc. fresh LOW Neurogene's financed Rett gene-therapy thesis turns on Embolden meeting its clinical endpoint in the second half of 2027 before a weekly close below $30 breaks the market structure. NRIX Nurix Therapeutics, Inc. fresh LOW Nurix Therapeutics' Roche-backed bexobrutideg story needs renewed clinical evidence after September's conference window. A weekly close above the $27.79 reference high would confirm the price leg; a weekly close below $24 would invalidate… NVCR NovoCure Limited fresh LOW NovoCure Limited’s commercial-inflection thesis requires another revenue-guidance increase and positive adjusted EBITDA at the next quarterly report. A weekly close below $15.40 invalidates the July repricing; unchanged guidance would fail… NVEC NVE Corporation LOW NVE Corporation’s recovery case depends on repeating June’s product-sales jump and reclaiming the lost $105 shelf. The next quarterly report must show product sales at or above $10,734,735 alongside a weekly close above $105 before a… ODTX Odyssey Therapeutics, Inc. fresh LOW Odyssey Therapeutics' OD-001 re-rating depends on October expansion data sustaining its reported ulcerative-colitis efficacy. Confirmation requires comparable results retaining 27% remission and 61% response at UEG Week on October 17–20,… OKLO Oklo Inc. LOW Three straight cohort-driven sessions carried OKLO from the 2026-07-29 close of $36.84 to $43.33 on 2026-08-04, with no Oklo release behind any of them. The 2026-08-07 Q2 call is the binary. ORIC Oric Pharmaceuticals, Inc. fresh LOW mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is… PESI Perma-Fix Environmental Services, Inc. fresh LOW Perma-Fix Environmental Services’ Hanford story needs Q3 revenue above $12.885 million and treatment revenue above $8.3 million to confirm waste-receipt conversion. A weekly close below $15 would invalidate the continuation thesis before… PI Impinj, Inc. fresh LOW Post-correction RAIN RFID recovery has extended to $138.37 (2026-07-17), holding the reclaimed $128 April gap-fill and pressing the $144.57 post-earnings high — but the entire near-term read is the 2026-07-29 Q2 print (guide $103–106M, EPS… PL Planet Labs PBC LOW Planet Labs’ satellite-data growth supports a tentative recovery case after the September 3 earnings beat failed to preserve its July range. A weekly close above $19.16 before a weekly close below $16.45 would establish the defined… PLAY Dave & Buster's Entertainment, Inc. fresh LOW Dave & Buster's recovery case requires positive comparable sales and a weekly reclaim of the September 4 close of $8.72 before a weekly close below $6.73 invalidates it. The September 18, 2026 close already breached the prior thesis's… PLTK Playtika Holding Corp. fresh LOW Playtika Holding Corp.'s remaining recovery case depends on completed refinancing and preserved revenue guidance. Confirmation requires execution of the authorized bond financing and retention of the $2.75 billion full-year revenue floor… PRLD Prelude Therapeutics Incorporated fresh LOW Prelude Therapeutics remains an Incyte option-exercise story: the $100 million fee would resolve the case positively if exercise precedes a weekly close below $4.75. September trial clearance adds pipeline progress, but the… QDEL QuidelOrtho Corporation fresh LOW QuidelOrtho’s recovery case requires a signed point-of-care divestiture and a weekly reclaim of $13.75 before a weekly close below $10.62. The earlier deal-rumor thesis had already breached its published price condition by September 18,… QURE uniQure N.V. fresh LOW FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA — the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on… RARE Ultragenyx Pharmaceutical Inc. fresh LOW The +50% June reset rally round-tripped from ~$33.46 to $28.62 (2026-07-21), parking price back on the breakout shelf ahead of two binary FDA decisions: DTX401 (GSD Ia) PDUFA Aug 23 and UX111 (Sanfilippo A) PDUFA Sep 19. The July 30 Q2… RBLX Roblox Corporation fresh LOW Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary — it needs a DAU… RCKT Rocket Pharmaceuticals, Inc. fresh LOW Rocket Pharmaceuticals’ Danon recovery case requires clinical progress at the 2026-10-06 webinar and a weekly recovery above $3.86 before a weekly close below $3.20. The September 15 FDA-alignment announcement narrows regulatory… RIVN Rivian Automotive, Inc. LOW Rivian Automotive’s recovery depends on its R2 second shift starting by September 30 and October deliveries exceeding Q2’s 12,194 vehicles while annual guidance remains 65,000–70,000. A weekly close below $12.90 invalidates the recovery… RLAY Relay Therapeutics, Inc. fresh LOW Relay Therapeutics' zovegalisib recovery case requires quantified Phase 3 enrollment progress by year-end 2026 and a weekly close above $20.75. A weekly close below $17.50 invalidates the case; the September 18 close of $18.84 has not… RLMD Relmada Therapeutics, Inc. fresh LOW Relmada Therapeutics’ NDV-01 re-rating thesis was invalidated by the $4.12 weekly close on 2026-09-18, below its published $4.25 shelf. A recovery above the March financing level and an announced IND submission would provide evidence for a… RPAY Repay Holdings Corporation fresh LOW The Visa-headline pop has round-tripped — $4.01 on 2026-08-21 back to $3.88 on 2026-09-04 — while the deal file stayed silent: the only company items since are an 2026-08-26 NxtEdge AP partnership and a 2026-09-03 IR hire, leaving… RZLT Rezolute, Inc. fresh LOW The August screener bid fully round-tripped: $5.09 on 2026-08-21 to $4.58 on 2026-09-04, back under the $4.60/$4.61 summer shelf, with no clinical news since 2026-06-17. The registrational upLIFT topline is still guided only to "2H-2026"… SANA Sana Biotechnology, Inc. LOW Type-1-diabetes functional-cure narrative: UP421's no-immunosuppression islet transplant is still producing insulin at 14 months (n=1), de-risking SC451's IND guided "as early as 2026." Rare-disease cell therapy is accelerating, but the… SEER Seer, Inc. fresh LOW The take-private ladder has stalled into a stand-off: the $2.55 Radoff-JEC bid lapsed unanswered on 2026-08-10, and the group's 2026-08-13 release demanding the board disclose an evaluation timeline has drawn no company reply through the… SLDB Solid Biosciences Inc. LOW Solid Biosciences’ SGT-003 thesis depends on functional Duchenne data supporting an accelerated-approval pathway. Favorable disclosed FDA feedback would validate the case; an adverse regulatory outcome or a weekly close below $8.00 would… SLN Silence Therapeutics Plc LOW Silence Therapeutics’ post-readout continuation thesis was invalidated by the 2026-09-11 weekly close of $13.02 below $13.50. Divesiran’s August clinical result remains relevant, but a renewed case requires price recovery and a disclosed… SMR NuScale Power Corporation LOW NuScale Power’s remaining case is a binding TVA power contract by end-2026 before a daily close below $7.96. The August-range recovery already failed when the shares closed at $8.61 on 2026-09-11, below the published $8.64 boundary. SPRB Spruce Biosciences, Inc. fresh LOW Spruce Biosciences’ Q4 2026 filing story depends on submitting its tralesinidase alfa application before a weekly close below $50. Management reiterated the window on 2026-09-15; submission by 2026-12-31 settles this filing case, while a… SPRY ARS Pharmaceuticals, Inc. LOW Single-product epinephrine name whose one catalyst — a July no-prior-auth formulary add for neffy — came and went unpaid; the stock has since broken its old $6.66 52-week low to fresh lows near $6. The neffy ramp is real but the access… STAA STAAR Surgical Company fresh LOW The re-rating leg failed and has not been re-bid: after the 2026-08-21 weekly close at $23.14 broke the $23.50 shelf, ten sessions produced only $23.47 on 2026-09-04 and a 2026-09-02 CTO appointment the tape ignored. What is left is a… STM STMicroelectronics N.V. fresh LOW The June AI-data-center re-rating has failed its retest: $62.06 on 2026-07-17 is -22% from the 2026-06-22 high of $79.82 and back under the early-June breakout base, with a $1.5B convertible overhang and a 7% selloff that ignored a BofA… STRO Sutro Biopharma, Inc. fresh LOW Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June… SYNA Synaptics Incorporated fresh LOW Synaptics' fixed-ratio onsemi merger remains the central thesis; completion on announced terms before a weekly close below $90 would validate it. The September 15 annual proxy does not establish a merger-vote date. TENX Tenax Therapeutics, Inc. LOW Tenax Therapeutics’ recovery case depends on FDA acceptance of an enriched LEVEL-2 design after the failed trial’s subgroup signal. An agreed protocol would substantiate the case; a weekly close below $1.70 would invalidate its market… TLRY Tilray Brands, Inc. fresh LOW Reform binary spent without resolving: the DEA hearing closed 2026-07-15 with only a 2026-08-17 briefing deadline and no ALJ timeline, so Schedule III is now an open-ended administrative process. TLRY printed a fresh 52-week low of $4.20… TMC TMC the metals company Inc. fresh LOW The deep-sea-mining reshoring leg is broken: TMC has cut through the $3.93 prior 52-week low to a fresh $3.57 low near $3.74, roughly -67% from the $11.35 high, with no bid and no near-term catalyst. The decisive NOAA license decision is… TSHA Taysha Gene Therapies, Inc. fresh LOW De-risking is behind the stock and the calendar in front of it is empty: after the clean 2026-06-22 data and the $6.00 June raise, no company-dated event lands before the ~November Q3 update, and the tape has drifted to a $5.60 close on… UI Ubiquiti Inc. fresh LOW Broken parabola gone flat: six weeks of $530–$570 chop after the May 8 print (GM 47.0%, rev +18.7%, but EPS $3.88 vs ~$4.42 whisper) with zero scheduled catalyst until the Q4 FY26 report on 2026-08-21. Fundamentals intact, tape dead,… VECO Veeco Instruments Inc. LOW Merger-arb tracking stock for Axcelis: fixed 0.3575 ACLS/VECO, both votes cleared 2026-02-06, only China SAMR remains before the 2026-09-30 outside date. ACLS's slide to ~$134 de-pegged VECO to a premium over the exchange ratio (~$48) —… VERI Veritone, Inc. fresh LOW Veritone’s rebound prices a negotiated resolution of its $45.6 million November debt maturity. The case plays out if repayment, refinancing or extension completes before 2026-11-15 and before a weekly close below $0.50; September’s… VIR Vir Biotechnology, Inc. fresh LOW Q2 (2026-08-05) printed $238.9M revenue and $0.47 diluted EPS on Astellas upfront recognition — an accounting swing, and the tape read it as one: $9.24 on 2026-08-14, still under the $10.36 Astellas equity strike, with Morgan Stanley and… VKTX Viking Therapeutics, Inc. LOW Viking Therapeutics' maintenance-dosing story needs September data showing retained weight loss with less frequent treatment and a weekly close above $34. The case fails on a weekly close below $30 or a missed September 30 readout window. VSH Vishay Intertechnology, Inc. LOW Cycle-turn re-rate has fully round-tripped: down ~46% from $69.47 to the high-$30s, now under the $50 June placement and below every covering analyst's target. Q1's 1.34 book-to-bill and $1.6B backlog were real but sit at ~35x forward into… WING Wingstop Inc. LOW Two analyst target cuts in ten days (Wells Fargo to $170, DA Davidson to $200) into the 2026-07-29 Q2 print signal de-risking ahead of the H2 comp-turn binary; a ~50% relief bounce off the $116.35 low is unproven, and the print — not… XENE Xenon Pharmaceuticals Inc. LOW Xenon Pharmaceuticals' recovery thesis requires an on-time azetukalner application and a weekly reclaim of the failed $62 shelf. Management guided submission to Q3 2026 on 2026-08-06; a weekly close below $55 or a disclosed filing delay… YSS York Space Systems Inc. LOW York Space Systems’ procurement-delay recovery case failed when its 2026-09-11 weekly close breached $8.86. Funded orders, backlog growth and recovery of that shelf are required to establish a new case. ZURA Zura Bio Limited LOW Zura Bio’s pipeline-expansion story depends on positive Q4 2026 TibuSHIELD data before a weekly close below $4.90 breaks the setup. The September 11 close of $5.21 and RSI of 39.2 weaken the price evidence; clinical confirmation requires a… ZVRA Zevra Therapeutics, Inc. LOW The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now…